133 related articles for article (PubMed ID: 16702510)
1. Peginterferon alfa-2b for mycosis fungoides.
Yanagi T; Shimizu T; Ujiie H; Ito M; Abe R; Tsuji-Abe Y; Hige S; Shimizu H
Arch Dermatol; 2006 May; 142(5):649-51. PubMed ID: 16702510
[No Abstract] [Full Text] [Related]
2. [Folliculotropic mycosis fungoides].
Baratli J; Balakirski G; Megahed M
Hautarzt; 2014 Dec; 65(12):1011-3. PubMed ID: 25355498
[TBL] [Abstract][Full Text] [Related]
3. Antiviral effect of peginterferon alfa-2b and alfa-2a compared.
Jansen PL; Reesink HW
J Hepatol; 2006 Aug; 45(2):172-3. PubMed ID: 16797101
[No Abstract] [Full Text] [Related]
4. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
5. Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides.
Walker CJ; Espinosa ML; Mehta-Shah N; Pro B; Guitart J; Kuzel T
J Drugs Dermatol; 2021 Mar; 20(3):349-350. PubMed ID: 33683074
[TBL] [Abstract][Full Text] [Related]
6. Widespread comedones as the sole clinical manifestation of follicular mycosis fungoides.
Torres T; Velho G; Alves R; Selores M
Eur J Dermatol; 2010; 20(4):534-5. PubMed ID: 20413371
[No Abstract] [Full Text] [Related]
7. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
[TBL] [Abstract][Full Text] [Related]
10. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
Santin M; Shaw E
Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812596
[No Abstract] [Full Text] [Related]
12. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
Picon PD; Costa AF; Kuchenbecker R; Beltrame A
Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812597
[No Abstract] [Full Text] [Related]
13. Interferon-based treatment for patients with mycosis fungoides and hepatitis C virus infection: a case series.
Kyvernitakis A; Duvic M; Mahale P; Torres HA
Am J Clin Dermatol; 2014 Oct; 15(5):451-6. PubMed ID: 24934807
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
Suzuki F; Toyota J; Ikeda K; Chayama K; Mochida S; Hayashi N; Ishikawa H; Miyagoshi H; Hu W; McPhee F; Hughes EA; Kumada H
Antivir Ther; 2014; 19(5):491-9. PubMed ID: 24451122
[TBL] [Abstract][Full Text] [Related]
15. Proceed with caution: peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials.
Kershenobich D; Muñoz L; Malé R; Gaytan J; Sánchez F
Hepatology; 2010 Dec; 52(6):2240-1; author reply 2241-2. PubMed ID: 21105116
[No Abstract] [Full Text] [Related]
16. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
Cecil BD
Lancet; 2002 Jan; 359(9302):263-4. PubMed ID: 11812598
[No Abstract] [Full Text] [Related]
17. [Pegasys: FDA approved Pegasys (peginterferon alfa-2a) for the treatment of hepatitis C].
Iafolla M
Sidahora; 2002; (4):8-10. PubMed ID: 12703472
[No Abstract] [Full Text] [Related]
18. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
Lindsay KL; Trepo C; Heintges T; Shiffman ML; Gordon SC; Hoefs JC; Schiff ER; Goodman ZD; Laughlin M; Yao R; Albrecht JK;
Hepatology; 2001 Aug; 34(2):395-403. PubMed ID: 11481625
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
